Read Full Article
Ra Pharmaceuticals today announced the appointment of Simon Read, PhD, as Chief Scientific Officer, effective April 4, 2016. ....
Ra's Extreme Diversity™ platform is based on a cutting edge chemistry that has yielded a deep pipeline of macrocyclic peptides with unique characteristics, including RA101495, where convenient subcutaneous dosing and potential for improved control of hemolysis can advance the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Simon brings a wealth of experience and knowledge across various stages of drug discovery and development, particularly in rare and orphan diseases.
We are excited to welcome Robert Heft and Tim Pearson to our Board of Directors, and we look forward to leveraging their vast experience as we continue development of our pipeline of complement inhibitors.